The Lung Cancer Therapeutics Market is increasingly being driven by the integration of molecular diagnostics with pharmaceutical treatment. Market Research Future estimates that the industry will expand from USD 29.84 billion in 2025 to USD 89.22 billion by 2035, representing an 11.5% CAGR. One of the most important changes behind this growth is the increasing use of biomarker and genomic information to guide therapy selection.

Next-generation sequencing is becoming an important part of lung cancer treatment workflows. Broad molecular profiling can identify mutations and alterations associated with treatment options, including EGFR, ALK, ROS1, BRAF, NTRK, RET, MET, and KRAS G12C. This has strengthened the connection between diagnostic companies and pharmaceutical developers.

The growth of targeted therapy is particularly significant. Rather than applying the same treatment approach across broad patient populations, targeted medicines are designed around specific molecular characteristics. This creates opportunities for pharmaceutical companies developing therapies against established and emerging genomic targets.

Immunotherapy is adding another dimension to treatment innovation. Checkpoint inhibitors have become an important component of advanced lung cancer treatment, while newer immuno-oncology combinations and bispecific therapies are expanding the pipeline. The report identifies immuno-oncology and bispecific development as the strongest contributor to market growth, adding an estimated 2.4 percentage points to CAGR.

Antibody-drug conjugates are also creating opportunities among patients who do not have clearly actionable driver mutations. Therapies directed toward targets such as TROP2, HER3, and MET could broaden the reach of precision oncology beyond traditional mutation-specific treatments.

Artificial intelligence is increasingly being incorporated into treatment planning and patient selection. Algorithms applied to pathology, radiology, and clinical data may help identify disease characteristics and predict treatment responses. These capabilities could eventually support more individualized treatment strategies while improving the efficiency of clinical workflows.

As diagnostics and therapeutics become more closely connected, the competitive landscape is likely to favor companies capable of combining medicines with companion diagnostics, genomic testing, and data-driven treatment strategies. This convergence is expected to remain a defining feature of lung cancer therapeutics through 2035.

Explore key developments shaping industry transformation:

Dermatophytic Onychomycosis Treatment Market Forecast

Pharmaceutical Cartridges Market Outlook

Trauma fixation devices Market Analysis

Plasma Therapy Market Distribution

Host Cell Contaminant Testing Market Size